CLAIMS

1. A pharmaceutical composition for subcutaneous, intramuscular or intradermal administration comprising coagulation factor VIIa.

2. The composition of claim 1 wherein the factor VIIa is recombinant human factor VIIa.

3. The composition of any of claims 1-2 which is for subcutaneous administration.

4. The composition of any of claims 1-3 wherein the composition further comprises a calcium salt.

5. The composition of any of claims 1-4 which is a stable aqueous solution ready for administration.

6. The composition of any of claims 1-4 which is dried and reconstituted with a pharmaceutical acceptable vehicle suitable for injection prior to administration.

7. A pharmaceutical composition for prolonging the biological half-life of FVIIa in a mammal, comprising FVIIa and a pharmaceutical acceptable carrier adapted for delivery of an effective dose of FVIIa to a patient in need thereof by subcutaneous, intramuscular or intradermal injection.

8. The composition of claim 7 wherein the factor VIIa is recombinant human factor VIIa.

9. The composition of any of claims 7-8 which is for subcutaneous administration.

10. The composition of any of claims 7-9 wherein the composition further comprises a calcium salt.

11. The composition of any of claims 7-10 which is a stable aqueous solution ready for administration.

12. The composition of any of claims 7-10 which is dried and reconstituted with a pharmaceutical acceptable vehicle suitable for injection prior to administration.

13. A method for treatment of a disease affectable by FVIIa by subcutaneously, intramuscularly or intradermally administering to a mammal in need thereof a composition comprising FVIIa.

14. The method of claim 13 where the disease is haemophilia A or B.

15. The method of any of claims 13-14 wherein the factor VIIa is recombinant human factor VIIa.

16. The method of any of claims 13-15 where the composition is administered subcutaneously.

17. The method of any of claims 13-16 where the composition is a stable aqueous solution ready for administration.

18. The method of any of claims 13-16 where the composition is dried and reconstituted with a pharmaceutical acceptable vehicle suitable for injection prior to administration.

19. A kit comprising FVIIa and a pharmaceutically acceptable carrier adapted for delivery of an effective dose of FVIIa to a patient in need thereof by subcutaneous, intramuscular or intradermal injection.

20. The kit of claim 19 where the patient is a haemophilia A or B patient.

21. The kit of any of claims 19-20 wherein the factor VIIa is recombinant human factor VIIa.

22. The kit of any of claims 19-21 where said injection is a subcutaneous injection.

23. Use of FVIIa for the manufacture of a composition according to claims 1-6 for treatment of diseases affectable by FVIIa.

24. Use of FVIIa for the manufacture of a composition of claims 7-12 for prolonging the biological half-life of FVIIa in a mammal.

25. A method for prolonging the biological half-life of FVIIa in a mammal, comprising administering FVIIa by subcutaneous, intramuscular or intradermal injection to a mammal in need thereof.

26. The method of claim 28 where the disease is haemophilia A or B.

27. The method of any of claims 28-29 where the FVIIa is administered by subcutaneous injection.

28. The method of any of claims 28-30 wherein the factor VIIa is recombinant human factor VIIa.

29. The method of any of claims 28-31 where the composition is administered subcutaneously.

30. The method of any of claims 28-32 where the composition is a stable aqueous solution ready for administration.

31. The method of any of claims 28-32 where the composition is dried and reconstituted with a pharmaceutical acceptable vehicle suitable for injection prior to administration.

add
A2